India Bans Promotion of Weight-Loss Drugs, Warns Pharma Firms

Central Drugs Standard Control Organisation (CDSCO) has directed pharmaceutical companies to immediately stop any direct or indirect promotion of weight-loss drugs, warning that violations could invite regulatory action.

The country’s drug regulator issued the advisory as demand for obesity treatments continues to grow and companies increasingly push these medicines through advertising and awareness campaigns.

The regulator clarified that promotion of weight-loss drugs is not allowed in any form under existing drug advertising rules. This includes advertisements on television, print, digital platforms, and social media. The advisory also targets surrogate promotions, where companies indirectly market prescription medicines through disease awareness campaigns or influencer messaging that encourages people to seek specific treatments.

Also Read: Advancing Interventional Radiology in India Through Collaboration

According to the regulator, some campaigns have exaggerated the benefits of obesity medicines while downplaying the importance of lifestyle changes such as diet control and physical activity. Officials warned that such promotions can mislead consumers and create unnecessary demand for prescription drugs that should only be used under medical supervision.

The directive comes at a time when global demand for obesity treatments, particularly GLP-1 based drugs, has surged. These medicines, originally developed to treat diabetes, are now widely used for weight management and have attracted significant interest from pharmaceutical companies looking to enter India’s growing obesity drug market.

CDSCO also cautioned companies against using doctors, influencers, or online platforms to indirectly recommend or promote prescription medicines for weight reduction. Any activity that pushes consumers toward a specific product or therapy may be treated as a violation of advertising rules.

By tightening oversight, the drug regulator aims to prevent misleading promotions and ensure that weight-loss drugs are prescribed only when medically necessary and under proper clinical guidance.